HC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $12 Price Target
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Microbot Medical (NASDAQ:MBOT) with a Buy and maintains $12 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Microbot Medical (NASDAQ:MBOT) with a Buy and maintains $12 price target.